C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

08 Apr 2024 08:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

09 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

04 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

12 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

28 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Chief Financial Officer Succession

05 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

05 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

20 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

30 May 2023 07:00:00 By Nasdaq GlobeNewswire